Can B Past Earnings Performance
Past criteria checks 0/6
Can B's earnings have been declining at an average annual rate of -18.5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 13.1% per year.
Key information
-18.5%
Earnings growth rate
60.1%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 13.1% |
Return on equity | n/a |
Net Margin | -985.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Can B makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 1 | -14 | 4 | 0 |
31 Mar 24 | 2 | -14 | 4 | 0 |
31 Dec 23 | 2 | -10 | 5 | 0 |
30 Sep 23 | 2 | -11 | 4 | 0 |
30 Jun 23 | 5 | -14 | 10 | 0 |
31 Mar 23 | 6 | -13 | 11 | 0 |
31 Dec 22 | 7 | -15 | 13 | 0 |
30 Sep 22 | 8 | -16 | 15 | 0 |
30 Jun 22 | 7 | -12 | 11 | 0 |
31 Mar 22 | 6 | -13 | 11 | 0 |
31 Dec 21 | 5 | -12 | 10 | 0 |
30 Sep 21 | 3 | -13 | 14 | 0 |
30 Jun 21 | 2 | -11 | 11 | 0 |
31 Mar 21 | 1 | -10 | 9 | 0 |
31 Dec 20 | 2 | -9 | 9 | 0 |
30 Sep 20 | 2 | -6 | 7 | 0 |
30 Jun 20 | 2 | -6 | 7 | 0 |
31 Mar 20 | 2 | -6 | 7 | 0 |
31 Dec 19 | 2 | -6 | 6 | 0 |
30 Sep 19 | 2 | -3 | 5 | 0 |
30 Jun 19 | 2 | -6 | 5 | 0 |
31 Mar 19 | 1 | -6 | 4 | 0 |
31 Dec 18 | 1 | -4 | 3 | 0 |
30 Sep 18 | 0 | -6 | 2 | 0 |
30 Jun 18 | 0 | -2 | 2 | 0 |
31 Mar 18 | 0 | -2 | 1 | 0 |
31 Dec 17 | 0 | -2 | 1 | 0 |
30 Sep 17 | 0 | -1 | 0 | 0 |
30 Jun 17 | 0 | -1 | 0 | 0 |
31 Mar 17 | 0 | 0 | 0 | 0 |
31 Dec 16 | 0 | -1 | 0 | 0 |
30 Sep 16 | 0 | -1 | 0 | 0 |
30 Jun 16 | 0 | -1 | 1 | 0 |
31 Mar 16 | 0 | -1 | 1 | 0 |
31 Dec 15 | 0 | -4 | 2 | 0 |
30 Sep 15 | 0 | -3 | 1 | 0 |
31 Dec 14 | 0 | 0 | 0 | 0 |
31 Dec 13 | 0 | 0 | 0 | 0 |
Quality Earnings: CANB is currently unprofitable.
Growing Profit Margin: CANB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CANB is unprofitable, and losses have increased over the past 5 years at a rate of 18.5% per year.
Accelerating Growth: Unable to compare CANB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CANB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Return on Equity
High ROE: CANB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.